Vitality Biopharma Shares Results for Cannabinoid Drug Formulations
Vitality Biopharma announced additional preclinical efficacy results for the treatment of colitis.
Your trusted source for investing success
Your trusted source for investing success
Vitality Biopharma announced additional preclinical efficacy results for the treatment of colitis.
By Pia Rivera
3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce the addition of Keith Cassidy to the Company’s board of directors and to the Company’s audit committee, effective immediately.
Tetra Bio-Pharma signed an agreement deal with Aphria to start promoting a co-developed medical cannabis blend product.
ProMIS Neurosciences provided an update from a preclinical study comparing PMN310 to other amyloid beta-directed antibodies combating Alzheimer’s disease.
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
By Jocelyn Aspa
Imagin Medical (CSE:IME) has announced that further to its press releases of September 26 and October 4, it is closing the second and final tranche of its non-brokered private placement for gross proceeds of $357,060.
As quoted in the press release:
Due to over-subscription, the Company will be closing on a total
By Jocelyn Aspa
InspireMD (NYSE:NSPR) has announced it has signed an agreement with CorpMedical Chile Ltda to distribute the MGuard Prime Embolic Protection System for the treatment of acute coronary syndromes.
As quoted in the press release:
Mr. Jaime Kehr, Chief Executive Officer of CorpMedical Chile Ltda, noted, “MGuard Prime™ with its MicroNet™ technology is
By Shelly Kumar
CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Harvest One Cannabis Inc.(TSXV:HVST) tremendous progress in growing its international footprint. The company’s wholly-owned United Greeneries subsidiary is awaiting approval from Health Canada for its ACMPR license to sell, but its
By Shelly Kumar
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI).
The note is available here: DMPI October 2017 Update.
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)) is a clinical-stage biotechnology firm
By Pia Rivera
3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”), is pleased to announce that, on September 30, 2017, the Company completed the clinical trial component (the “Clinical Trial”), or Stage 3, of its Hodgkin’s lymphoma (“HL”) test (“Telo-HLTM”) validation program.
The world’s pharmaceutical industry is dominated by the American and European markets. According to Forbes top companies of 2017, the 10 biggest drug companies are all located in these two regions.
At the halfway mark of 2017, here’s a look at how these four gene therapy companies are performing so far this year.
By Micha Boon
3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce the close of its non-brokered private placement (the “Private Placement”) of 2,000,000 common shares (the “Shares”) at a price of C $0.25 per Share for gross proceeds of C $500,000 with ScreenCell SA (“ScreenCell”), announced October
By Shelly Kumar
Harvest One Cannabis Inc.(TSXV:HVST) is pleased to provide a market update on its wholly owned subsidiary, Satipharm AG (“Satipharm”):
Satipharm has received German “Free Sales Certificate” reducing constraints for international export
Australian Regulatory Authority has issued final approval for CBD capsule prescription in Australia
Strong increase in European dietary supplement
What options exist for investors who want to invest in biotechnology? From stocks to ETFs, there are plenty of choices.
By Micha Boon
3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the “Company” or “3DS”) is pleased to announce a non-brokered private placement (the “Private Placement”) of 2,000,000 common shares (the “Shares”) at a price of C $0.25 per Share for gross proceeds of C $500,000 with ScreenCell SA (“ScreenCell”).
ScreenCell, a strategic partner to 3DS,
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held October 1-4, 2017 in Pittsburgh, PA. The poster entitled “Distinct mechanism of
By Jocelyn Aspa
Here, INN looks at the four top performing 3D printing stocks on the NASDAQ year-to-date.
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
